Not Signed In - Avicena Advances Clinical Development Of HD-02 For Huntington's Disease
Wed, 13 Dec 2006 08:00 AM EST
... Avicena Group, Inc. (OTC Bulletin Board: AVGO), a biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today the initiation of a chronic toxicology study of HD-02, its lead candidate for Huntington's disease (HD). [click link for full article] ...
Related Topics
- Huntington's Disease
- Clinical Trials
- Child Development
- Fetal Development
- Teen Development
- Infectious Diseases
- Community Development
- Guaifenesin, Hydrocodone, and Pseudoephedrine
- Crohn's Disease
- Chlorpheniramine, Hydrocodone and Phenylephrine Liquid
- Pharmacology
- Psychopharmacology
- Infant and Toddler Development
- Diseases & Conditions
- Clinical Growth Charts
- Heart Disease
- Epidemiology
- Phenylephrine and Guaifenesin ER Tablets
- Bone Disease
- Vaccine Development
email this page
print this page
bookmark this page
feedback on this page
